![]() However, topical minoxidil preparations are associated with frequent side effects as scalp pruritus or irritation and a bothersome facial hypertrichosis (Blume-Peytavi et al. The trichogenic effects of minoxidil can be explained by its ability to increase the anagen phase and decrease the telogen phase of the hair cycle, to promote the rate of hair growth and through its augmented proliferative and vasodilatory actions (Messenger and Rundegren 2004). Then in 2014, topical minoxidil at 5% concentration was approved by both the FDA and Health Canada for FPHL (Kanti et al. Initially, the Food and Drug Administration (FDA) has approved the twice-daily application of 1 ml of topical minoxidil 2% solution to treat FPHL (Blumeyer et al. Clinically, FPHL patients show a reduced hair density over the crown and frontal scalp with preservation of anterior hairline or what is commonly described as “Christmas tree” pattern (Blume-Peytavi et al. ![]() The disease can evolve early in young women before menarche or later in the 6th decade of life (Olsen et al. Female pattern hair loss (FPHL) is a non-scarring alopecia characterized by gradual and progressive miniaturization of hair follicles or terminal to villus hair shift (Trueb 2002). Subsequently, female alopecia exhibits a devastating impact on quality of life (Tabolli et al. Since ancient times, there is no doubt that hair is one of the most determining features of a woman’s appearance. IRB approval status: reviewed and approved by IRB of Faculty of Medicine, Zagazig University approval no. Further studies should evaluate the efficacy of higher concentrations of ketoconazole solutions for FPHL which is a promising therapy. However, ketoconazole showed a delayed improvement versus minoxidil at similar concentrations. Topical ketoconazole mediates a trichogenic effect in FPHL with few side effects. Patients’ satisfaction did not differ between the two groups. Only 10% of Group B reported side effects. While in Group B, the improvement was delayed until the 6th month. Regarding hair growth, a significant difference was detected between baseline and at 4th and 6th months in Group A. Side effects were recorded, and patients’ satisfaction was measured. All patients were treated for 6 months and evaluated clinically plus via trichoscopy. Patients were randomly assigned into Group A with 20 patients who received 2% topical minoxidil solution and Group B involving 20 patients who were treated by 2% topical ketoconazole preparation. The aim of this work was to evaluate the safety and possible trichogenic effects of ketoconazole in FPHL. Ketoconazole is an antifungal with anti-androgenic properties. Topical minoxidil is the only approved treatment for FPHL however, it has frequent side effects. Symptoms of invasive candidiasis.Female pattern hair loss (FPHL) is a common non-scaring alopecia. Candidiasis.Ĭenters for Disease Control and Prevention. National Organization for Rare Disorders. Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity. Okada S, Puel A, Casanova JL, Kobayashi M. doi:10.3390/pharmacy10010029Ĭenters for Disease Control and Prevention. ![]() Towards better CARE for superficial fungal infections: A consultation guide for the community pharmacy. Parinyarux P, Thavornwattanayong W, Soontornpas C, Rawangnam P. Candidiasis (mucocutaneous).Ĭlancy CJ, Nguyen MH. Living in your skin: Microbes, molecules, and mechanisms.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |